We use cookies to help make our website work. LEARN MORE


You can delete your alerts anytime

Albumedix helps biopharmaceutical companies improve patient outcomes with a range of albumin-based products and technologies that facilitate the development of superior biotherapeutics.

Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years’ experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline.

Albumedix is a global company and a fully owned subsidiary of Novozymes.


Albumedix Ltd
59 Castle Boulevard

Phone: 0115 955 3379

Website: Albumedix